On September 12, 2024, the U.S. Food and Drug Administration (FDA) announced its approval of Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) for subcutaneous injection, commonly known as a shot. This approval included all the same uses of Tecentriq (atezolizumab) that the FDA previously approved for adults, including treatments for both non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). 

This latest approval is based on the results of the IMscin001 study, which compared the use of Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) given by a shot (injection) under the skin in the thigh versus Tecentriq (atezolizumab) which is an infusion into the bloodstream (intravenous/IV). People given Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as a shot received the drug over approximately 7 minutes compared to the standard 30-60 minutes when Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) is given by IV. 

The study showed no difference in the drug’s safety or efficacy between the two administration methods. The follow-up IMscin002 study also showed that 71% of participants preferred the shot over IV injection.

Tecentriq (atezolizumab) is a medication previously approved for use in adults for several indications, including NSCLC and SCLC. Adding Hybreza (hyaluronidase-tqjs) to the shot helps improve the absorption and dispersion of Tecentriq (atezolizumab) within the body.

Please speak with your healthcare team for more information about Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) to see if it may be a good option for you. If you have questions about treatment, trials, or biomarker testing, contact our LungMATCH team at support@go2.org or 1-800-298-2436. 

Read the full FDA announcement.